MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer
Go back to MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer| MACROGENICS (NASDAQ: MGNX) | Delayed: 4.12 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.12 | 52 Week High | $36.11 | |||
| Open | $4.12 | 52 Week Low | $14.84 | |||
| Day High | $4.12 | P/E | 10.56 | |||
| Day Low | $4.12 | EPS | $0.39 | |||
| Volume | 262 | |||||

